A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice
MetadataShow full item record
AbstractVaccine studies for Shigella flexneri and enterotoxigenic Escherichia coli have been impaired by the lack of optimal animal models. We used two murine models to show that a S. flexneri 2a bivalent vaccine (CVD 1208S-122) expressing enterotoxigenic Escherichia coli colonization factor antigen-I (CFA/I) and the binding subunits A2 and B of heat labile-enterotoxin (LTb) is immunogenic and protects against weight loss and diarrhea. These findings document the immunogenicity and pre-clinical efficacy effects of CVD 1208S-122 vaccine and suggest that further work can help elucidate relevant immune responses and ultimately its clinical efficacy in humans. Copyright 2020, The Author(s).
SponsorsThis work was supported by National Institutes of Health (NIH) under NIH Award Number U19 AI109776 (CETR, Centers for Excellence for Translational Research, PI Myron Levine) from the National Institute of Allergy and Infectious Diseases (NIAID); and by Bill & Melinda Gates Foundation under Opportunity ID OPP1137923 (Host, pathogen and pathogen interaction determinants of environmental enteric dysfunction). National Institutes of Health, NIH: U19 AI109776 Israeli Centers for Research Excellence, I-CORE
Enterotoxigenic Escherichia coli
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082751265&doi=10.1038%2fs41541-020-0180-y&partnerID=40&md5=7a53678d7e4654fc0dd7f859c9ad2e00; http://hdl.handle.net/10713/12537